| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H19F3N6O |
| Molecular Weight | 392.3783 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@](C)(NC1=NC(=NC=C1)C2=CNC3=NC=CC=C23)C(=O)NCC(F)(F)F
InChI
InChIKey=ASUGUQWIHMTFJL-QGZVFWFLSA-N
InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1
| Molecular Formula | C18H19F3N6O |
| Molecular Weight | 392.3783 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Decernotinib is taken orally and its dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg.
Route of Administration:
Oral
Human T-Cells were plated plated in T75 tissue culture flasks at a density of 1*10(6)/ml. Cells were stimulated with 10 mg/ml phytohemagglutinin at 37C for 72 hours. After 72 hours, cells were detached from the flask by scraping, washed, and plated at a density of 1*10(5)/well in a 96-well plate. decernotinib (9.7 nM to 10 uM) was added, and plates were incubated for 30 minutes at 37C, followed by stimulation with human IL-2. Human B cells were thawed, washed, and resuspended in complete medium. Cells were plated onto a 96-well plate at a density of 2*10(5) cells/well. Decernotinib was added, and plates were incubated for 30 minutes at 37C, followed by stimulation with a combination of 10 ng/ml IL-4 and 1 ug/ml CD40.
Showing 1 to 1 of 1 entries
